{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166104949",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166104949",
    "name" : "CPIC Guideline for warfarin and CYP2C9,VKORC1",
    "history" : [ {
      "id" : 1183699782,
      "date" : "2011-09-07T00:00:00-07:00",
      "type" : "create",
      "version" : 0
    }, {
      "id" : 1183701832,
      "date" : "2013-12-18T00:00:00-08:00",
      "description" : "Added note about recent publications",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1183846974,
      "date" : "2014-02-27T00:00:00-08:00",
      "description" : "changed URL of dosing algorithm",
      "type" : "correction",
      "version" : 1
    }, {
      "id" : 1184470001,
      "date" : "2014-06-19T00:00:00-07:00",
      "type" : "update",
      "version" : 0
    } ],
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA451906",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA451906",
      "name" : "warfarin",
      "version" : 12
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA126",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA126",
      "symbol" : "CYP2C9",
      "name" : "cytochrome P450, family 2, subfamily C, polypeptide 9",
      "version" : 7874
    }, {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA133787052",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA133787052",
      "symbol" : "VKORC1",
      "name" : "vitamin K epoxide reductase complex, subunit 1",
      "version" : 14
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447981868,
      "externalLinks" : [ "http://www.warfarindosing.org" ],
      "html" : "<p>The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.warfarindosing.org\" target=\"_blank\">http://www.warfarindosing.org</a></p>\n",
      "internalLinks" : [ ],
      "markdown" : "The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on [http://www.warfarindosing.org]",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 2
    },
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447981867,
      "externalLinks" : [ "http://www.warfarindosing.org", "https://cpicpgx.org", "https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/21900891-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/21900891.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/IWPC_dose_calculator.xls" ],
      "html" : "<h3 id=\"november-2013-update\">November 2013 Update</h3>\n<p>CPIC guideline authors are aware of several recently published studies on warfarin pharmacogenetics [Articles:<a href=\"/pmid/24251361\">24251361</a>, <a href=\"/pmid/24251363\">24251363</a>, <a href=\"/pmid/24251360\">24251360</a>]. These papers have prompted several opinion pieces [Articles:<a href=\"/pmid/24328463\">24328463</a>, <a href=\"/pmid/24251364\">24251364</a>]. The authors are evaluating the information, which will be incorporated into the next update of the CPIC guideline on warfarin.</p>\n<h3 id=\"october-2011\">October 2011</h3>\n<p><em>Advance online publication September 2011.</em></p>\n<ul>\n<li>Guideline regarding the use of pharmacogenomic tests in dosing for warfarin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org\" target=\"_blank\">(CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adult patients</li>\n</ul>\n</li>\n<li>Excerpt from the 2011 warfarin dosing guideline:\n<ul>\n<li>&quot;Pharmacogenetic algorithm-based warfarin dosing: Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:<a href=\"/pmid/18305455\">18305455</a>, <a href=\"/pmid/19228618\">19228618</a>, <a href=\"/pmid/18574025\">18574025</a>]. Two algorithms perform well in estimating stable warfarin dose across different ethnic populations; [Articles:<a href=\"/pmid/18305455\">18305455</a>, <a href=\"/pmid/19228618\">19228618</a>] these were created using more than 5,000 subjects. Dosing algorithms using genetics outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction [Articles:<a href=\"/pmid/18305455\">18305455</a>, <a href=\"/pmid/19228618\">19228618</a>]. The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.warfarindosing.org\" target=\"_blank\">http://www.warfarindosing.org</a> (offering both high-performing algorithms [Articles:<a href=\"/pmid/18305455\">18305455</a>, <a href=\"/pmid/19228618\">19228618</a>]). The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium is also online, at <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fwarfarin%2F2011%2FIWPC_dose_calculator.xls\" target=\"_blank\">IWPC Pharmacogenetic Dosing Algorithm</a>. The two algorithms provide very similar dose recommendations.&quot;</li>\n<li>&quot;Approach to pharmacogenetic-based warfarin dosing without access to dosing algorithms:     In 2007, the FDA modified the warfarin label, stating that CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial dose of warfarin [Article:<a href=\"/pmid/17906972\">17906972</a>]. The label was further updated in 2010 to include a table (Table 1) describing recommendations for initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:<a href=\"/pmid/21272753\">21272753</a>]. Therefore, the use of pharmacogenetic algorithm-based dosing is recommended when possible, although if electronic means for such dosing are not available, the table-based dosing approaches (Table 1) are suggested. The range of doses by VKORC1 genotype and the range of dose recommendations/predictions by the FDA table and algorithm are shown in Figure 2.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fwarfarin%2F2011%2F21900891.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fwarfarin%2F2011%2F21900891-supplement.pdf\" target=\"_blank\">2011 supplement</a></li>\n<li>Look up your warfarin dosing guideline using the <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fwarfarin%2F2011%2FIWPC_dose_calculator.xls\" target=\"_blank\">IWPC Pharmacogenetic Dosing Algorithm</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"figure-2-frequency-histograms-of-stable-therapeutic-warfarin-doses-in-mg-week-stratified-by-vkorc1-1639g-a-genotype\">Figure 2. Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G&gt;A genotype.</h3>\n<p><em>Adapted from Figure 2 of the 2011 guideline manuscript</em></p>\n<p><img src=\"https://s3.pgkb.org/attachment/Figure_2-CPIC_Warfarin_dosing_guidelines.png\" alt=\"CPIC warfarin dosing guideline\" /></p>\n<p><strong>Figure 2 Legend:</strong> Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by <em>VKORC1</em> -1639G&gt;A genotype in 3,616 patients recruited by the International Warfarin Pharmacogenetics Consortium (IWPC) who did not carry the <em>CYP2C9*2</em> or <em>*3</em> allele (i.e., coded as <em>*1/*1</em> for US Food and Drug Administration (FDA) table and algorithm dosing). The range of doses within each genotype group recommended on the FDA table is shown via the shaded rectangle. The range of doses predicted using the IWPC dosing algorithm in these 3,616 patients is shown by the solid lines.</p>\n<p>Figure 2 demonstrates that the range of individuals covered by the FDA table is much narrower than that of the algorithm. The article and supplement detail important variables that are not covered by the table that should also be taken into consideration.</p>\n<h3 id=\"table-1-recommended-daily-warfarin-doses-mg-day-to-achieve-a-therapeutic-inr-based-on-cyp2c9-and-vkorc1-genotype-using-the-warfarin-product-insert-approved-by-the-united-states-food-and-drug-administration\">Table 1: Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on <em>CYP2C9</em> and <em>VKORC1</em> genotype using the warfarin product insert approved by the United States Food and Drug Administration:</h3>\n<p><em>Adapted from Table 1 of the 2011 guideline manuscript</em></p>\n<table class=\"table\">\n<thead>\n<tr><th><em>VKORC1</em> Genotype (-1639G&gt;A, <a href=\"/variant/PA166155091\">rs9923231</a>)</th><th><em>CYP2C9*1/*1</em></th><th><em>CYP2C9*1/*2</em></th><th><em>CYP2C9*1/*3</em></th><th><em>CYP2C9*2/*2</em></th><th><em>CYP2C9*2/*3</em></th><th><em>CYP2C9*3/*3</em></th></tr>\n</thead>\n<tbody>\n<tr><td>GG</td><td>5-7</td><td>5-7</td><td>3-4</td><td>3-4</td><td>3-4</td><td>0.5-2</td></tr>\n<tr><td>GA</td><td>5-7</td><td>3-4</td><td>3-4</td><td>3-4</td><td>0.5-2</td><td>0.5-2</td></tr>\n<tr><td>AA</td><td>3-4</td><td>3-4</td><td>0.5-2</td><td>0.5-2</td><td>0.5-2</td><td>0.5-2</td></tr>\n</tbody>\n</table>\n<p><em>Reproduced from updated warfarin (Coumadin) product label.</em></p>\n<h3 id=\"supplemental-table-s1-genotypes-that-constitute-the-alleles-for-cyp2c9\">Supplemental Table S1. Genotypes that constitute the * alleles for <em>CYP2C9</em></h3>\n<p><em>Adapted from Table S1 of the 2011 guideline supplement</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele</th><th>Constituted by genotypes at:</th><th>Amino acid changes</th><th>Enzymatic Activity</th></tr>\n</thead>\n<tbody>\n<tr><td>*1</td><td>reference allele at all positions</td><td></td><td>Normal</td></tr>\n<tr><td>*2</td><td>C&gt;T at <a href=\"/variant/PA166153972\">rs1799853</a></td><td>R144C</td><td>Decreased</td></tr>\n<tr><td>*3</td><td>A&gt;C at <a href=\"/variant/PA166153959\">rs1057910</a></td><td>I359L</td><td>Decreased</td></tr>\n</tbody>\n</table>\n",
      "internalLinks" : [ "!^attachment/Figure_2-CPIC_Warfarin_dosing_guidelines.png" ],
      "markdown" : "## November 2013 Update\r\n\r\nCPIC guideline authors are aware of several recently published studies on warfarin pharmacogenetics [PMID: 24251361, 24251363, 24251360]. These papers have prompted several opinion pieces [PMID: 24328463, 24251364]. The authors are evaluating the information, which will be incorporated into the next update of the CPIC guideline on warfarin.\r\n\r\n## October 2011\r\n\r\n_Advance online publication September 2011._ \r\n- Guideline regarding the use of pharmacogenomic tests in dosing for warfarin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](https://cpicpgx.org).  \r\n- These guidelines are applicable to:\r\n  - adult patients\r\n- Excerpt from the 2011 warfarin dosing guideline:\r\n  - \"Pharmacogenetic algorithm-based warfarin dosing: Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [PMID: 18305455, 19228618, 18574025]. Two algorithms perform well in estimating stable warfarin dose across different ethnic populations; [PMID: 18305455, 19228618] these were created using more than 5,000 subjects. Dosing algorithms using genetics outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction [PMID: 18305455, 19228618]. The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on [http://www.warfarindosing.org] (offering both high-performing algorithms [PMID: 18305455, 19228618]). The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium is also online, at [IWPC Pharmacogenetic Dosing Algorithm](https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/IWPC_dose_calculator.xls). The two algorithms provide very similar dose recommendations.\"\r\n  - \"Approach to pharmacogenetic-based warfarin dosing without access to dosing algorithms:     In 2007, the FDA modified the warfarin label, stating that CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial dose of warfarin [PMID:17906972]. The label was further updated in 2010 to include a table (Table 1) describing recommendations for initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [PMID:21272753]. Therefore, the use of pharmacogenetic algorithm-based dosing is recommended when possible, although if electronic means for such dosing are not available, the table-based dosing approaches (Table 1) are suggested. The range of doses by VKORC1 genotype and the range of dose recommendations/predictions by the FDA table and algorithm are shown in Figure 2.\"\r\n- Download and read: \r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing](https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/21900891.pdf)\r\n  - [2011 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/21900891-supplement.pdf)\r\n  - Look up your warfarin dosing guideline using the [IWPC Pharmacogenetic Dosing Algorithm](https://github.com/PharmGKB/cpic-guidelines/raw/master/warfarin/2011/IWPC_dose_calculator.xls).\r\n\r\n## Figure 2. Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G>A genotype.\r\n\r\n_Adapted from Figure 2 of the 2011 guideline manuscript_\r\n\r\n![CPIC warfarin dosing guideline](^Figure_2-CPIC_Warfarin_dosing_guidelines.png)\r\n\r\n__Figure 2 Legend:__ Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by _VKORC1_ -1639G>A genotype in 3,616 patients recruited by the International Warfarin Pharmacogenetics Consortium (IWPC) who did not carry the _CYP2C9*2_ or _*3_ allele (i.e., coded as _*1/*1_ for US Food and Drug Administration (FDA) table and algorithm dosing). The range of doses within each genotype group recommended on the FDA table is shown via the shaded rectangle. The range of doses predicted using the IWPC dosing algorithm in these 3,616 patients is shown by the solid lines.\r\n\r\nFigure 2 demonstrates that the range of individuals covered by the FDA table is much narrower than that of the algorithm. The article and supplement detail important variables that are not covered by the table that should also be taken into consideration.\r\n\r\n\r\n\r\n## Table 1: Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on _CYP2C9_ and _VKORC1_ genotype using the warfarin product insert approved by the United States Food and Drug Administration:\r\n\r\n_Adapted from Table 1 of the 2011 guideline manuscript_\r\n\r\n| _VKORC1_ Genotype (-1639G>A, [variant:rs9923231]) | _CYP2C9*1/*1_ | _CYP2C9*1/*2_ | _CYP2C9*1/*3_ | _CYP2C9*2/*2_ | _CYP2C9*2/*3_ | _CYP2C9*3/*3_| \r\n| --- | --- | --- | --- | --- | --- | --- |\r\n| GG | 5-7 | 5-7 | 3-4 | 3-4 | 3-4 | 0.5-2|\r\n| GA | 5-7 | 3-4 | 3-4 | 3-4 | 0.5-2 | 0.5-2|\r\n| AA | 3-4  | 3-4 | 0.5-2 | 0.5-2 | 0.5-2 | 0.5-2|\r\n\r\n_Reproduced from updated warfarin (Coumadin) product label._\r\n\r\n## Supplemental Table S1. Genotypes that constitute the * alleles for _CYP2C9_\r\n\r\n_Adapted from Table S1 of the 2011 guideline supplement_\r\n\r\n| Allele | Constituted by genotypes at:| Amino acid changes | Enzymatic Activity |\r\n| --- | --- | --- | --- |\r\n| *1 | reference allele at all positions | | Normal | \r\n| *2 | C>T at [variant:rs1799853] | R144C | Decreased | \r\n| *3 | A>C at [variant:rs1057910] | I359L | Decreased |",
      "pmids" : [ "17906972", "18305455", "18574025", "19228618", "21272753", "24251360", "24251361", "24251363", "24251364", "24328463" ],
      "relatedObjects" : [ "PA166153959", "PA166153972", "PA166155091" ],
      "version" : 7
    },
    "version" : 21,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983518,"resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-warfarin-and-cyp2c9-and-vkorc1%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"} ]
  }
}